|

entinostat Clinical Trials

2 actively recruiting trials across 1 location

Also known as: HDAC inhibitor SNDX-275, MS 27-275, MS 275, MS-275, MS275, SNDX 275, SNDX-275, SNDX275

Other1 trial

A Phase II Clinical Study Evaluating Entinostat With or Without Anlotinib + Fulvestrant for the Treatment of Hormone Receptor (HR) -Positive, Human Epidermal Growth Factor Receptor-2 (HER-2) -Negative Advanced Breast Cancer That Relapsed or Progressed After Endocrine Therapy
Phase 2

New Haven, Connecticut1 trial

Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors

Yale University

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.